Open AccessValidity and clinical impact of glucose transporter 1 expression in colorectal cancer
Author(s) -
Ghada M K GabAllah,
Mona Salah Eldin Habib,
Shimaa E. Soliman,
Zeinab A. Kasemy,
Suzy Gohar
Publication year - 2017
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/sjg.sjg_197_17
Subject(s) - medicine , glut1 , biomarker , colorectal cancer , oncology , stage (stratigraphy) , metastasis , gastroenterology , cancer , glucose transporter , biology , paleontology , biochemistry , insulin
There is no doubt that colorectal cancer (CRC) poses a major threat to public health worldwide, and despite improvement in managements, prognosis still remains an irritating question with no definite answer. Being a fundamental player in cancer metabolism, glucose transporter 1 (GLUT1) could be utilized as a prognostic biomarker that could fuel development of new treatment strategies. The aim of this study was to assess the validity of GLUT1 expression as a prognostic biomarker and to elucidate to what extent it is immersed in poor clinical outcome among CRC patients.